Home LiteratureArticle Details
PMID: 12163589 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Consistent patterns in the development and immunodominance of human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T-cell responses following acute HIV-1 infection.

Journal of virology ·Vol. 76 ·No. 17 ·2002-09-00 ·Pages 8690-701

Yu XG, Addo MM, Rosenberg ES, Rodriguez WR, Lee PK, Fitzpatrick CA, Johnston MN, Strick D, Goulder PJ, Walker BD, Altfeld M

Abstract

Human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T-cell responses generated during acute infection play a critical role in the initial control of viremia. However, little is known about the viral T-cell epitopes targeted during acute infection or about their hierarchy in appearance and relative immunodominance over time. In this study, HIV-1-specific CD8+ T-cell responses in 18 acutely infected individuals expressing HLA-A3 and/or -B7 were characterized. Detailed analysis of CD8 responses in one such person who underwent treatment of acute infection followed by reexposure to HIV-1 through supervised treatment interruptions (STI) revealed recognition of only two cytotoxic T-lymphocyte (CTL) epitopes during symptomatic acute infection. HIV-1-specific CD8+ T-cell responses broadened significantly during subsequent exposure to the virus, ultimately targeting 27 distinct CTL epitopes, including 15 different CTL epitopes restricted by a single HLA class I allele (HLA-A3). The same few peptides were consistently targeted in an additional 17 persons expressing HLA-A3 and/or -B7 during acute infection. These studies demonstrate a consistent pattern in the development of epitope-specific responses restricted by a single HLA allele during acute HIV-1 infection, as well as persistence of the initial pattern of immunodominance during subsequent STI. In addition, they demonstrate that HIV-1-specific CD8+ T-cell responses can ultimately target a previously unexpected and unprecedented number of epitopes in a single infected individual, even though these are not detectable during the initial exposure to virus. These studies have important implications for vaccine design and evaluation.

MeSH Terms
Acute Disease Amino Acid Sequence Antiretroviral Therapy, Highly Active CD8-Positive T-Lymphocytes/immunology Cell Line Drug Administration Schedule HIV Infections/drug therapy,immunology,virology HIV-1/chemistry,immunology HLA-A3 Antigen/metabolism HLA-B7 Antigen/metabolism Humans Immunodominant Epitopes/chemistry,immunology Molecular Sequence Data Peptides/chemical synthesis,chemistry,immunology Viral Proteins/chemical synthesis,chemistry,immunology
Chemicals
HLA-A3 Antigen HLA-B7 Antigen Immunodominant Epitopes Peptides Viral Proteins
Authors & Affiliations
11 authors, click to expand affiliations / ORCID
Yu Xu G
Partners AIDS Research Center and Infectious Disease Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Addo Marylyn M
Rosenberg Eric S
Rodriguez William R
Lee Paul K
Fitzpatrick Cecily A
Johnston Mary N
Strick Daryld
Goulder Philip J R
Walker Bruce D
Altfeld Marcus
References (47)
47 references, click to expand
  1. Memory CD8+ T cells in HIV infection.
    Philos Trans R Soc Lond B Biol Sci. 2000 Mar 29;355(1395):363-7 PMID: 10794056
  2. Autologous strain-specific cytolytic T lymphocyte responses directed against human immunodeficiency virus type 1 Env.
    AIDS Res Hum Retroviruses. 1998 Jan 1;14(1):3-13 PMID: 9453246
  3. Liver-derived CTL in hepatitis C virus infection: breadth and specificity of responses in a cohort of persons with chronic infection.
    J Immunol. 1998 Feb 1;160(3):1479-88 PMID: 9570570
  4. HLA supertypes and supermotifs: a functional perspective on HLA polymorphism.
    Curr Opin Immunol. 1998 Aug;10(4):478-82 PMID: 9722926
  5. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes.
    Science. 1999 Feb 5;283(5403):857-60 PMID: 9933172
  6. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques.
    J Exp Med. 1999 Mar 15;189(6):991-8 PMID: 10075982
  7. HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression.
    Nat Med. 1999 May;5(5):518-25 PMID: 10229228
  8. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy.
    J Clin Invest. 1999 Sep;104(6):R13-8 PMID: 10491418
  9. Anti-HIV cellular immunity: recent advances towards vaccine design.
    AIDS. 1999;13 Suppl A:S121-36 PMID: 10885771
  10. The role of CD4(+) T helper cells in the cytotoxic T lymphocyte response to HIV-1.
    Curr Opin Immunol. 2000 Aug;12(4):375-80 PMID: 10899028
  11. Cytotoxic T lymphocyte responses to human immunodeficiency virus: control and escape.
    Stem Cells. 2000;18(4):230-44 PMID: 10924089
  12. Identification of dominant optimal HLA-B60- and HLA-B61-restricted cytotoxic T-lymphocyte (CTL) epitopes: rapid characterization of CTL responses by enzyme-linked immunospot assay.
    J Virol. 2000 Sep;74(18):8541-9 PMID: 10954555
  13. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia.
    Nature. 2000 Sep 21;407(6802):386-90 PMID: 11014195
  14. Immune control of HIV-1 after early treatment of acute infection.
    Nature. 2000 Sep 28;407(6803):523-6 PMID: 11029005
  15. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination.
    Science. 2000 Oct 20;290(5491):486-92 PMID: 11039923
  16. Functionally inert HIV-specific cytotoxic T lymphocytes do not play a major role in chronically infected adults and children.
    J Exp Med. 2000 Dec 18;192(12):1819-32 PMID: 11120778
  17. Early programming of T cell populations responding to bacterial infection.
    J Immunol. 2000 Dec 15;165(12):6833-9 PMID: 11120806
  18. CD8(+) lymphocytes from simian immunodeficiency virus-infected rhesus macaques recognize 14 different epitopes bound by the major histocompatibility complex class I molecule mamu-A*01: implications for vaccine design and testing.
    J Virol. 2001 Jan;75(2):738-49 PMID: 11134287
  19. Rapid definition of five novel HLA-A*3002-restricted human immunodeficiency virus-specific cytotoxic T-lymphocyte epitopes by elispot and intracellular cytokine staining assays.
    J Virol. 2001 Feb;75(3):1339-47 PMID: 11152507
  20. Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection.
    J Exp Med. 2001 Jan 15;193(2):181-94 PMID: 11148222
  21. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection.
    J Exp Med. 2001 Jan 15;193(2):169-80 PMID: 11148221
  22. New insights into host factors in HIV-1 pathogenesis.
    Cell. 2001 Feb 23;104(4):473-6 PMID: 11239405
  23. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.
    Science. 2001 Apr 6;292(5514):69-74 PMID: 11393868
  24. Cellular immune responses to HIV.
    Nature. 2001 Apr 19;410(6831):980-7 PMID: 11309628
  25. Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naïve cells.
    Nat Immunol. 2001 May;2(5):415-22 PMID: 11323695
  26. Naïve CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation.
    Nat Immunol. 2001 May;2(5):423-9 PMID: 11323696
  27. HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection.
    AIDS. 2001 Jun 15;15(9):F19-27 PMID: 11416734
  28. The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection.
    AIDS. 2001 Jun 15;15(9):F29-40 PMID: 11416735
  29. Perspectives on inducing efficient immune control of HIV-1 replication--a new goal for HIV therapeutics?
    AIDS. 2001 Feb;15 Suppl 2:S36-42 PMID: 11424975
  30. Less is more? STI in acute and chronic HIV-1 infection.
    Nat Med. 2001 Aug;7(8):881-4 PMID: 11479610
  31. Vpr is preferentially targeted by CTL during HIV-1 infection.
    J Immunol. 2001 Sep 1;167(5):2743-52 PMID: 11509618
  32. Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects.
    Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13288-93 PMID: 11687611
  33. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.
    Nature. 2002 Jan 17;415(6869):331-5 PMID: 11797011
  34. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes.
    Nature. 2002 Jan 17;415(6869):335-9 PMID: 11797012
  35. HIV-specific cytotoxic T lymphocytes in seropositive individuals.
    Nature. 1987 Jul 23-29;328(6128):345-8 PMID: 3496541
  36. Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with human immunodeficiency virus type 1.
    Proc Natl Acad Sci U S A. 1989 Dec;86(23):9514-8 PMID: 2480604
  37. Definition of an epitope and MHC class I molecule recognized by gag-specific cytotoxic T lymphocytes in SIVmac-infected rhesus monkeys.
    J Immunol. 1991 Jul 1;147(1):320-9 PMID: 1711081
  38. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.
    J Virol. 1994 Jul;68(7):4650-5 PMID: 8207839
  39. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection.
    J Virol. 1994 Sep;68(9):6103-10 PMID: 8057491
  40. MHC ligands and peptide motifs: first listing.
    Immunogenetics. 1995;41(4):178-228 PMID: 7890324
  41. Antigenic oscillations and shifting immunodominance in HIV-1 infections.
    Nature. 1995 Jun 15;375(6532):606-11 PMID: 7791879
  42. Comprehensive, serologically equivalent DNA typing for HLA-B by PCR using sequence-specific primers (PCR-SSP).
    Tissue Antigens. 1995 Feb;45(2):81-90 PMID: 7792765
  43. Overlapping epitopes in human immunodeficiency virus type 1 gp120 presented by HLA A, B, and C molecules: effects of viral variation on cytotoxic T-lymphocyte recognition.
    J Virol. 1997 Feb;71(2):1256-64 PMID: 8995649
  44. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus.
    Nat Med. 1997 Feb;3(2):205-11 PMID: 9018240
  45. Identification of type-specific cytotoxic T lymphocyte responses to homologous viral proteins in laboratory workers accidentally infected with HIV-1.
    J Clin Invest. 1997 Feb 15;99(4):752-62 PMID: 9045880
  46. Degenerate and promiscuous recognition by CTL of peptides presented by the MHC class I A3-like superfamily: implications for vaccine development.
    J Immunol. 1997 Aug 15;159(4):1648-57 PMID: 9257824
  47. HLA-B57-restricted cytotoxic T-lymphocyte activity in a single infected subject toward two optimal epitopes, one of which is entirely contained within the other.
    J Virol. 2000 Jun;74(11):5291-9 PMID: 10799606
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
Published
2002-09-00
Pages
8690-701
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC136975
Subset
IM
Grants
NIAID NIH HHS · R01 AI040873 · United States
NIAID NIH HHS · R01 AI44656 · United States
NIAID NIH HHS · R01 AI30914 · United States
NIAID NIH HHS · R01 AI50429 · United States
NIAID NIH HHS · R37 AI125568 · United States
NIAID NIH HHS · R01 AI40873 · United States
NIAID NIH HHS · R01 AI050429 · United States
NIAID NIH HHS · R01 AI044656 · United States
NIAID NIH HHS · R01 AI030914 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com